New Latex CRP Assay

A new c-reactive protein (CRP) latex assay has been developed as an independent cardiac risk marker. The assay has been cleared by the U.S. Food and Drug Administration (FDA).

The new assay was developed by Olympus Diagnostic Systems Group (Melville, NY, USA), whose parent company is Olympus Corp. (Tokyo, Japan). Olympus notes that highly sensitive application measurements when used in conjunction with traditional clinical laboratory evaluations maybe useful as an independent marker of prognosis for recurrent events in patients with either stable coronary disease or acute coronary syndromes.

C-reactive protein is one of the most sensitive acute-phase reactants. Measurement of CRP can play a role in the detection and evaluation of infection, tissue injury, and inflammatory disorders and related diseases. The CRP latex assay offers three applications covering a variety of measuring ranges to quantify CRP in human serum: normal (5 to 170 mg/l), sensitive (0.5 to -20 mg/l), and highly sensitive (neonatal, 0.05 to 2.00 mg/l). The assay can be run on the full line of Olympus chemistry-immuno analyzers.

Olympus offers a broad line of random access chemistry-immuno analyzers along with lab automation systems, comprehensive patient safety systems, blood bank analyzers, and reagents.




Related Links:
Olympus Diagnostic Systems